Navigating the CMS 14-Day Rule in Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. David Rimm and Roy Herbst review the problems with the CMS “14-Day Rule” since some of the multigene panel biomarker tests require 21 days or longer to complete.
Dr Agarwala discusses the optimal approach to providing information on targeted therapies to the oncology community.
Drs Geoffrey Oxnard and Lauren Ritterhouse discuss the challenges and opportunities of precision medicine and molecular biomarkers in their clinical practice from an oncologist’s and a pathologist’s perspective.